Related Experiment Video
Updated: Jun 22, 2026
07:13
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Predictive models in diagnosing indolent cancer
Chris H Bangma1, Monique J Roobol, Ewout W Steyerberg
1Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands. h.j.vanalphen@erasmusmc.nl
Cancer
|June 23, 2009
Summary
Predicting indolent prostate cancer is crucial to prevent overtreatment. Current nomograms require further validation for widespread clinical use in identifying low-risk tumors.
Area of Science:
- Oncology
- Urology
Background:
- Early prostate cancer detection increases the incidence of indolent tumors.
- Indolent prostate cancers are unlikely to cause symptoms or mortality.
- Overtreatment of indolent prostate cancer leads to unnecessary invasive therapies.
Purpose of the Study:
- To review existing nomograms for predicting indolent prostate cancer.
- To assess the applicability of current prediction tools for clinical use.
Main Methods:
- Systematic review of published nomograms predicting indolent prostate cancer.
- Analysis of nomogram validation based on clinical versus screening patient series.
Main Results:
- Many nomograms are based on limited clinical patient series, restricting generalizability.
- Nomograms derived from general population screening require further validation.
- Current tools have limitations in accurately predicting indolent tumors for broad application.
Conclusions:
- Accurate prediction of indolent prostate cancer is essential for appropriate patient management.
- Existing nomograms need further validation, especially those based on screening data.
- Improved prediction tools are necessary to guide treatment decisions and active surveillance.
